Clinical

The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.

The combination of olomorasib and pembrolizumab to treat KRAS G12C-mutant advanced NSCLC showed promising antitumor activity.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.

Explore the evolving landscape of desmoid tumor treatments, highlighting surgery, cryotherapy, and radiotherapy for effective patient care.

Experts discuss the complexities of observing desmoid tumors, weighing the benefits of active surveillance against the need for immediate treatment.

Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and targeted therapies, while identifying immunotherapy as a major unmet need and expressing optimism about patients achieving long-term survival on current regimens.

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Lenacapavir and cabotegravir are among the most important advancements in HIV prevention and treatment within the past 10 years.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.

The group describes the clinical gaps that prompted development of bispecifics and summarizes the currently available agents for relapsed/refractory disease.

Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.

Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.

Mirvetuximab soravtansine, particularly in combination regimens, showed promising efficacy and an acceptable safety profile in recurrent ovarian cancer.

Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.

Pigment epithelial detachment and hyperreflective foci had better early control in age-related macular degeneration (AMD) when treated with faricimab.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.